These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites. Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912 [TBL] [Abstract][Full Text] [Related]
8. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors. Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022 [TBL] [Abstract][Full Text] [Related]
9. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs. Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites. Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors. Yoshikawa K; Yoshino T; Yokomizo Y; Uoto K; Naito H; Kawakami K; Mochizuki A; Nagata T; Suzuki M; Kanno H; Takemura M; Ohta T Bioorg Med Chem Lett; 2011 Apr; 21(7):2133-40. PubMed ID: 21345673 [TBL] [Abstract][Full Text] [Related]
12. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors. Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification. Komoriya S; Kobayashi S; Osanai K; Yoshino T; Nagata T; Haginoya N; Nakamoto Y; Mochizuki A; Nagahara T; Suzuki M; Shimada T; Watanabe K; Isobe Y; Furugoori T Bioorg Med Chem; 2006 Mar; 14(5):1309-30. PubMed ID: 16263291 [TBL] [Abstract][Full Text] [Related]
14. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors. Franciskovich JB; Masters JJ; Weber WW; Klimkowski VJ; Chouinard M; Sipes PR; Johnson LM; Snyder DW; Chastain MK; Craft TJ; Towner RD; Gifford-Moore DS; Froelich LL; Smallwood JK; Foster RS; Smith GF; Liebeschuetz JW; Murray CW; Young SC Bioorg Med Chem Lett; 2007 Dec; 17(24):6910-3. PubMed ID: 17976987 [TBL] [Abstract][Full Text] [Related]
15. Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores. Kotian PL; Krishnan R; Rowland S; El-Kattan Y; Saini SK; Upshaw R; Bantia S; Arnold S; Babu YS; Chand P Bioorg Med Chem; 2009 Jun; 17(11):3934-58. PubMed ID: 19409795 [TBL] [Abstract][Full Text] [Related]
16. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa. Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Nagamochi M; Kobayashi S; Komoriya S; Yokomizo A; Muto R; Yamaguchi M; Osanai K; Suzuki M; Kanno H Bioorg Med Chem; 2009 Feb; 17(3):1193-206. PubMed ID: 19128974 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160 [TBL] [Abstract][Full Text] [Related]
18. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. Kleanthous S; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chan C; Clarte MO; Convery MA; Harling JD; Hortense E; Irving WR; Irvine S; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Roethka TJ; Senger S; Shah GP; Stelman GJ; Toomey JR; Watson NS; West RI; Whittaker C; Zhou P; Young RJ Bioorg Med Chem Lett; 2010 Jan; 20(2):618-22. PubMed ID: 20006499 [TBL] [Abstract][Full Text] [Related]
19. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512 [TBL] [Abstract][Full Text] [Related]
20. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides. Chan C; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chung CW; Convery MA; Hamblin JN; Johnstone L; Kelly HA; Kleanthous S; Patikis A; Patel C; Pateman AJ; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Whitworth C; Young RJ; Zhou P J Med Chem; 2007 Apr; 50(7):1546-57. PubMed ID: 17338508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]